This webinar will outline the current state of the art in the application of continuous crystallisation technologies to isolate, purify and engineer relevant properties of active pharmaceutical ingredients (APIs) such as particle size distribution, morphology and polymorphic form of small molecule drugs with specific reference to how the process dynamics of continuous crystallisers can control and lead to a wider choice of critical product attributes for APIs than when only batch crystallisation and isolation options are considered.
Steven started as an undergraduate in chemical & bioprocess engineering in University College Dublin (UCD) and stayed there to do his PhD, where he currently holds the position of assistant professor. Following on from his PhD, he moved to MIT as a postdoctoral researcher, working on the development of continuous manufacturing technologies to intensify pharmaceutical production. After MIT, Steven moved across the street to the other side of Kendall square, to work on drug development in Biogen, a large biopharmaceutical company. This role focused on the development and commercialisation of drugs for neurological and immunological conditions and was part of what would be considered a very small team within the industry to bring drug candidates from discovery through trials, to commercialisation. Steven is a Lecturer/Assistant Professor at the School of Chemical and Bioprocess Engineering at UCD and his current research group are developing multidisciplinary approaches and technologies informed by his own experience. This would differ from the ‘traditional’ path of the single expert working in a narrow field of science or engineering.
Stevens expertise includes but is not limited to:
Neurology and immunology
You can learn more about Steven’s work at https://scholar.google.com/citations?hl=en&user=3J4EoM0AAAAJ